Eversept Partners, LP Milestone Pharmaceuticals Inc. Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2023	SELL	$5.86 - $9.43 $119,186 - $191,796	-20,339 Reduced 13.82%	126,826 $1 Million
Q3 2022 Nov 14, 2022	SELL	$5.86 - $9.43 $119,186 - $191,796	-20,339 Reduced 13.82%	126,826 $1.17 Million
Q1 2022 Nov 08, 2023	BUY	$4.1 - $8.24 $603,376 - $1.21 Million	147,165 New	147,165 $944,000
Q4 2021 Nov 08, 2023	BUY	$5.47 - $7.13 $183,616 - $239,339	33,568 Added 29.55%	147,165 $963,000
Q4 2021 Feb 14, 2022	BUY	$5.47 - $7.13 $183,616 - $239,339	33,568 Added 29.55%	147,165 $964,000
Q3 2021 Nov 08, 2023	BUY	$5.28 - $6.29 $599,792 - $714,525	113,597 New	113,597 $648,000
Q3 2021 Nov 15, 2021	BUY	$5.28 - $6.29 $599,792 - $714,525	113,597 New	113,597 $649,000

28.7M

200

Ticker MIST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,010,900
Market Cap $70.8M
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.